Skip to main content
Premium Trial:

Request an Annual Quote

Julian Parkhill, Carol Churcher, Harold Swerdlow, Jane Rogers, Peter Pohl, Marcus Benz, Christof von Kalle, Dirk Honold, Thomas Pohl

The Wellcome Trust Sanger Institute has appointed a new senior management team for DNA sequencing.
Julian Parkhill, head of the pathogen sequencing unit, has become director of sequencing. His role will be “to support the new management team, to give strategic direction, and to promote the important interactions between the institute’s faculty Investigators and the sequencing group,” according to the Sanger Institute.
Carol Churcher is the new head of sequencing operations. She is a senior manager in the pathogen sequencing unit and joined the institute when it was founded in 1993. Previously, she worked at the MRC Laboratory of Molecular Biology.
Harold Swerdlow has become head of sequencing technology. Until early 2006, he was senior director of research at Solexa, which became part of Illumina last year. Swerdlow holds a PhD in bioengineering from the University of Utah.
Jane Rogers, human sequencing and mapping project manager, left the Sanger Institute last year, according to an institute spokesperson. Rogers was also a member of the board of management.

Peter Pohl has become CEO of LifeCode, a new personal genomics spinoff from German sequencing service provider GATC Biotech (see feature article in this issue). He is also the CEO of GATC Biotech.
Pohl and Marcus Benz, GATC’s chief operating officer, are members of LifeCode’s board of directors. Christof von Kalle, a professor at the University of Freiburg, Germany; Dirk Honold, a professor at the University of Applied Science in Nuremberg, Germany; and Thomas Pohl, GATC’s CTO, are members of the company’s supervisory board, according to LifeCode’s website.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more